Friday, June 12, 2015

TrovaGene - All Time High

TrovaGene (TROV) is the Barchart Chart of the Day.  The biomedical company has a Trend Spotter buy signal, a Weighted Alpha of 319.00+ and gained 250.66% in the last year.

The Chart of the Day is TrovaGene (TROV).  I found the stock by using Barchart to sort today's All Time High list for the stocks with the best technical buy signals, then used the Flipchart feature to review the charts.  Since the Trend Spotter signaled a buy on 5/1 the stock gained 56.17%.

TrovaGene is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Their patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism.

The status of Barchart's Opinion trading systems are listed below.  Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates.  The indicator numbers shown below therefore may not match what you see live on the web site when you read this report.

Barchart technical indicators:

  • 100% Barchart technical buy signals
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 8 new highs and up 17.51% in the last month'
  • Relative Strength Index 75.75%
  • Barchart computes a technical support level at 12.02
  • Recently traded at 13.29 with a 50 day moving average of 9.57
Fundamental factors:
  • Market Cap $323.88 million
  • Revenue expected to grow 435.70% this year and another 428.00% next year
  • Earnings estimated to increase 13.10% next year
  • Wall Street analysts issued 1 strong buy and 3 buy recommendations on the stock
I'd advise you use a trailing stop loss 10% below the most recent high to protect your gains.

No comments:

Post a Comment